Evidence map›Paper›PMID 26483167›Full record

ReviewNature reviews. Cardiology2015

Mitral valve disease--morphology and mechanisms.

Robert A Levine, Albert A Hagége, Daniel P Judge, Muralidhar Padala, Jacob P Dal-Bianco, Elena Aikawa, Jonathan Beaudoin, Joyce Bischoff, Nabila Bouatia-Naji, Patrick Bruneval and 33 more

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 7 pooled it
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 7 syntheses or guidelines pooled it, 373 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Immune Mechanisms of Heart Valve Development, Homeostasis, and Disease.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Mechanisms of mitral valve development and disease.Frontiers in cardiovascular medicine · 2026
    Review
  20. Review

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 18 institutions in 9 countries.

Robert A LevineCardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 5E, Boston, MA 02114, USA.
Albert A HagégeHôpital Européen Georges Pompidou, Université René Descartes, UMR 970, Paris, France.
Daniel P JudgeJohns Hopkins University, Baltimore, MD, USA.
Muralidhar PadalaEmory University School of Medicine, Atlanta, GA, USA.
Jacob P Dal-BiancoMassachusetts General Hospital, Cardiac Ultrasound Laboratory, Harvard Medical School, Boston, MA, USA.
Elena AikawaBrigham and Women's Hospital, Boston, MA, USA.
Jonathan BeaudoinLaval Hospital, Quebec City, Canada.
Joyce BischoffBoston Children's Hospital, Boston, MA, USA.
Nabila Bouatia-NajiHôpital Européen Georges Pompidou, Université René Descartes, UMR 970, Paris, France.
Patrick BrunevalHôpital Européen Georges Pompidou, Université René Descartes, UMR 970, Paris, France.
Jonathan T ButcherCornell University, Ithaca, NY, USA.
Alain CarpentierHôpital Européen Georges Pompidou, Université René Descartes, UMR 970, Paris, France.
Miguel ChaputUniversity of Montreal, Montreal, Canada.
Adrian H ChesterImperial College London, London, UK.
Catherine CluselINSERM-Transfert, Paris, France.
Francesca N DellingBeth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA.
Harry C DietzJohns Hopkins University, Baltimore, MD, USA.
Christian DinaUniversity of Nantes, Thoracic Institute, INSERM UMR 1097, CNRS UMR 6291, Nantes, France.
Ronen DurstHadassah-Hebrew University Medical Centre, Jerusalem, Israel.
Leticia Fernandez-FrieraHospital Universitario HM Monteprincipe and the Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC), Madrid, Spain.
Mark D HandschumacherMassachusetts General Hospital, Cardiac Ultrasound Laboratory, Harvard Medical School, Boston, MA, USA.
Morten O JensenUniversity of Aarhus, Aarhus, Denmark.
Xavier P JeunemaitreHôpital Européen Georges Pompidou, Université René Descartes, UMR 970, Paris, France.
Hervé Le MarecUniversity of Nantes, Thoracic Institute, INSERM UMR 1097, CNRS UMR 6291, Nantes, France.
Thierry Le TourneauUniversity of Nantes, Thoracic Institute, INSERM UMR 1097, CNRS UMR 6291, Nantes, France.
Roger R MarkwaldMedical University of South Carolina, Charleston, SC, USA.
Jean MérotUniversity of Nantes, Thoracic Institute, INSERM UMR 1097, CNRS UMR 6291, Nantes, France.
Emmanuel MessasHôpital Européen Georges Pompidou, Université René Descartes, UMR 970, Paris, France.
David P MilanCardiovascular Research Center, Harvard Medical School, Boston, MA, USA.
Tui NeriAix-Marseille University, INSERM UMR 910, Marseille, France.
Russell A NorrisMedical University of South Carolina, Charleston, SC, USA.
David PealCardiovascular Research Center, Harvard Medical School, Boston, MA, USA.
Maelle PerrocheauHôpital Européen Georges Pompidou, Université René Descartes, UMR 970, Paris, France.
Vincent ProbstUniversity of Nantes, Thoracic Institute, INSERM UMR 1097, CNRS UMR 6291, Nantes, France.
Michael PucéatAix-Marseille University, INSERM UMR 910, Marseille, France.
Nadia RosenthalEuropean Molecular Biology Laboratory, Monterotondo, Italy.
Jorge SolisHospital Universitario HM Monteprincipe and the Centro Nacional de Investigaciones Cardiovasculares, Carlos III (CNIC), Madrid, Spain.
Jean-Jacques SchottUniversity of Nantes, Thoracic Institute, INSERM UMR 1097, CNRS UMR 6291, Nantes, France.
Ehud SchwammenthalTel Aviv University, Tel Aviv, Israel.
Susan A SlaugenhauptCenter for Human Genetic Research, MGH Research Institute, Harvard Medical School, Boston, MA, USA.
Jae-Kwan SongAsan Medical Centre, Seoul, South Korea.
Magdi H YacoubImperial College London, London, UK.
Leducq Mitral Transatlantic Network
Harvard University · USImperial College London · GBJohns Hopkins University · USMedical University of South Carolina · USSpanish National Centre for Cardiovascular Research · ESAarhus University · DKAix-Marseille Université · FRAsan Medical Center · KRBoston Children's Hospital · USBrigham and Women's Hospital · USCornell University · USEmory University · USEuropean Molecular Biology Laboratory · ITHebrew University of Jerusalem · ILInserm · FRInserm Transfert · FRTel Aviv University · ILUniversité de Montréal · CA

Funding

Targeted Nano-therapeutics for Neural RegenerationP20GM103444 · NIGMS · CLEMSON UNIVERSITY · PI NORRIS, RUSSELL · 2012 to 2018
$14.9M
SC COBRE for Developmentally Based Cardiovascular DiseasesP30GM103342 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KERN, MICHAEL J · 2012 to 2016
$5.5M
UNDERSTANDING AND CONTROLLING TISSUE-SPECIFIC VASCULAR PATTERNINGP20RR021949 · NCRR · CLEMSON UNIVERSITY · PI MARKWALD, ROGER R · 2009 to 2011
$5.2M
MUCOPOLYSACCHRIDE METABOLISM IN CARDIAC ANOMALIESR01HL033756 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MARKWALD, ROGER R · 1985 to 2015
$4.8M
Effect of Mitral Regurgitation on Ischemic LV RemodelingR01HL072265 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LEVINE, ROBERT A · 2003 to 2013
$3.5M
Improving Mitral Compensation in Ischemic RegurgitationR01HL109506 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI AIKAWA, ELENA, BISCHOFF, JOYCE E. · 2012 to 2015
$3.3M
Genetics and Mechanisms of Mitral Valve ProlapseR01HL127692 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILAN, DAVID J, SLAUGENHAUPT, SUSAN A · 2015 to 2018
$3.0M
Treating Ventricle and Valve: New Synergies for Ischemic LV Remodeling with MRR01HL128099 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI AKAR, FADI GABRIEL, LEVINE, ROBERT A · 2016 to 2019
$2.8M
NEW TARGETED THERAPIES FOR ISCHEMIC MITRAL REGURGITATIONR01HL038176 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LEVINE, ROBERT A · 1998 to 2008
$2.8M
Aortic valve microcalcificationR01HL114805 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2012 to 2016
$2.1M
ISCHEMIC MITRAL REGURGITATION: FROM MECHANISM TO THERAPYK24HL067434 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LEVINE, ROBERT A · 2001 to 2011
$1.6M
Genetic Determinants and Progression of Mitral Valve ProlapseK23HL116652 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DELLING, FRANCESCA N · 2014 to 2018
$699k
NCRR NIH HHS P20 RR021949NHLBI NIH HHS K23 HL116652NHLBI NIH HHS K24 HL067434NHLBI NIH HHS R01 HL033756NHLBI NIH HHS R01 HL038176NHLBI NIH HHS R01 HL072265NHLBI NIH HHS R01 HL109506NHLBI NIH HHS R01 HL114805NHLBI NIH HHS R01 HL127692NHLBI NIH HHS R01 HL128099NHLBI NIH HHS R01 HL72265NIGMS NIH HHS P20 GM103444NIGMS NIH HHS P30 GM103342
6 · The paper itself

Abstract

Mitral valve disease is a frequent cause of heart failure and death. Emerging evidence indicates that the mitral valve is not a passive structure, but--even in adult life--remains dynamic and accessible for treatment. This concept motivates efforts to reduce the clinical progression of mitral valve disease through early detection and modification of underlying mechanisms. Discoveries of genetic mutations causing mitral valve elongation and prolapse have revealed that growth factor signalling and cell migration pathways are regulated by structural molecules in ways that can be modified to limit progression from developmental defects to valve degeneration with clinical complications. Mitral valve enlargement can determine left ventricular outflow tract obstruction in hypertrophic cardiomyopathy, and might be stimulated by potentially modifiable biological valvular-ventricular interactions. Mitral valve plasticity also allows adaptive growth in response to ventricular remodelling. However, adverse cellular and mechanobiological processes create relative leaflet deficiency in the ischaemic setting, leading to mitral regurgitation with increased heart failure and mortality. Our approach, which bridges clinicians and basic scientists, enables the correlation of observed disease with cellular and molecular mechanisms, leading to the discovery of new opportunities for improving the natural history of mitral valve disease.

Indexed as

Mitral Valve InsufficiencyHumans

Identifiers

PMID26483167
PMCPMC4804623
OpenAlexW1754892555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.